Kopran Limited shareholders approved a final dividend of ₹3 per equity share of face value ₹10 each during the company's 67th annual general meeting held on August 18, 2026. The virtual meeting, conducted via video conferencing, also saw the re-appointment of director Varun Somani and the appointment of Namrata Somani to the board.

All five ordinary resolutions placed before the members were passed with overwhelming support. The promoter group, holding over 97% of the voting power, cast 100% of its votes in favor of every agenda item. Public non-institutional shareholders also backed the proposals, with approval rates exceeding 96% across all resolutions.

Key Resolutions Passed

The meeting addressed the following business items:

• Adoption of audited standalone financial statements for FY26
• Adoption of audited consolidated financial statements for FY26
• Declaration of final dividend for FY26
• Re-appointment of Varun Somani as director
• Appointment of Namrata Somani as director

The statutory auditors' report and secretarial audit report for FY26 were noted to be free of qualifications.

Voting Results

The combined results of remote e-voting and e-voting conducted during the meeting reflect strong shareholder alignment with management proposals. The promoter group participated fully in the voting process.

Smita Prabhu & Associates served as the scrutinizer for the meeting. The complete voting results and scrutinizer's report have been filed with the stock exchanges and are available on the company's website.

Kopran reported a 10% year-on-year decline in consolidated net profit to ₹670.09 lakh for the first quarter ended June 30, 2026 (Q1FY26), despite top-line revenue growing to ₹1,539.94 lakh. The pharmaceutical manufacturer’s Board of Directors approved the unaudited standalone and consolidated financial results on August 7, 2026, revealing that rising input costs and operational expenses eroded operating leverage. While absolute earnings before interest, tax, depreciation, and amortisation (EBITDA) improved to ₹178.39 lakh, the EBITDA margin contracted by 67 basis points to 11.55% from 12.22% in the corresponding quarter of FY25. The results were reviewed by statutory auditor Khandelwal Jain & Co., which issued an unmodified opinion.

Revenue and Operating Performance

Kopran’s consolidated revenue from operations rose 13.8% year-on-year to ₹1,539.94 lakh in Q1FY26, compared to ₹1,352.16 lakh in Q1FY25. This growth was driven by increased volume and mix improvements across its pharmaceutical portfolio. However, the cost of materials consumed surged significantly to ₹1,208.91 lakh from ₹803.02 lakh in the previous year’s quarter, reflecting inflationary pressures in raw material costs. Employee benefits expense also increased to ₹184.63 lakh from ₹154.33 lakh, while other expenses rose to ₹285.64 lakh from ₹202.49 lakh. These cost increases outpaced revenue growth, leading to a compression in operating margins.

On a standalone basis, Kopran’s revenue from operations grew more sharply by 22.2% to ₹627.58 lakh from ₹513.35 lakh in Q1FY25. Standalone EBITDA margin remained relatively stable but showed signs of pressure, with total expenses rising to ₹568.88 lakh from ₹485.25 lakh. The company benefited from foreign exchange gains of ₹197.62 lakh on a consolidated basis and ₹258.39 lakh on a standalone basis, which partially offset the operating margin contraction.

The following table summarises Kopran’s key financial metrics for Q1FY26:

Note: EBITDA calculated as Total Income minus Total Expenses plus Depreciation/Amortisation/Finance Costs where applicable per standard definition implied by source data structure.

Profitability and Bottom Line

Despite the revenue growth, Kopran’s consolidated net profit declined to ₹670.09 lakh in Q1FY26 from ₹744.93 lakh in Q1FY25, a decrease of approximately 10%. The profit before tax stood at ₹880.29 lakh, down from ₹988.91 lakh in the prior year quarter. Tax expense for the period was ₹193.25 lakh (current tax) and ₹16.95 lakh (deferred tax), totaling ₹210.20 lakh.

In contrast, the standalone segment saw a significant improvement in net profit, which more than doubled to ₹672.30 lakh from ₹351.81 lakh in Q1FY25. This divergence highlights the impact of inter-company transactions and subsidiary performance on the consolidated bottom line. Basic earnings per share (EPS) for the consolidated entity fell to ₹1.39 from ₹1.54 in Q1FY25, while standalone basic EPS rose to ₹1.39 from ₹0.73.

What the Numbers Show

The primary challenge for Kopran in Q1FY26 was margin erosion due to disproportionate growth in material costs. While revenue grew by nearly 14%, the cost of materials consumed jumped by over 50%, indicating either a shift towards higher-cost products or significant inflation in key active pharmaceutical ingredients (APIs). The contraction in consolidated EBITDA margin from 12.22% to 11.55% underscores this pressure. However, the strong standalone profit growth suggests that the parent company’s direct operations are performing well, with efficiencies or better pricing power not fully reflected in the consolidated group results due to subsidiary dynamics. Foreign exchange gains provided a modest tailwind, contributing ₹197.62 lakh to consolidated income, but were insufficient to fully counteract the operating headwinds.